GLP-1 eligibility
GLP-1 receptor agonists are not appropriate for everyone. Eligibility rests on BMI thresholds together with weight-related comorbidities, and there are absolute contraindications that rule the class out entirely.
What a provider evaluates
- BMI, and whether weight-related comorbidities are present at a lower threshold
- Personal or family history of medullary thyroid carcinoma or MEN2 — an absolute contraindication
- History of pancreatitis
- Pregnancy, planned pregnancy or breastfeeding
- Diabetic medication regimen and hypoglycaemia risk
What treatment may involve
- A branded GLP-1 therapy where you meet criteria
- An alternative metabolic approach where the class is not appropriate
- A decline, where treatment is not clinically indicated
Whether any of these is appropriate is determined by a licensed provider after reviewing your history and laboratory results.
Medications a provider may consider
Semaglutide
Semaglutide is a GLP-1 receptor agonist prescribed for weight management. Learn how it is dosed, what monitoring it needs, and what a provider assesses first.
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist used in weight management. Learn how it differs from semaglutide and what evaluation it requires.
Questions about glp-1 eligibility
Am I eligible for GLP-1 therapy?
Eligibility generally rests on BMI thresholds, with a lower threshold applying where weight-related comorbidities are present. There are also absolute contraindications: a personal or family history of medullary thyroid carcinoma or MEN2 rules the class out entirely, and a history of pancreatitis requires careful consideration. A provider determines eligibility after reviewing your intake and laboratory results, and not everyone qualifies.
Do you offer compounded semaglutide or tirzepatide?
Not as a general offering. The FDA declared the semaglutide and tirzepatide shortages resolved, which ended the basis on which pharmacies could compound copies of them, and enforcement discretion for outsourcing facilities ended in March 2025. What remains available is the FDA-approved branded product, and genuine patient-specific compounding only where a prescriber documents a clinical need the approved product cannot meet. Any provider offering compounded copies as a routine low-cost alternative is operating outside that framework.